Empowering the Immunocompromised and Elderly: ExeVir Bio presents promising XVR013 datam at ID Week 2024
XVR013m, a broadly neutralizing VHH-FC antibody consistently shows exceptional neutralization potency across both SARS-CoV-2 pre-Omicron and Omicron variants
Ghent, Belgium, 17 October 2024: ExeVir Bio, a biotech company developing robust heavy chain-only antibody therapies for broad protection against infectious diseases, is pleased to announce its participation in ID Week 2024, where it will present a poster on XVR013m, a potent VHH-Fc antibody for the prevention and treatment of COVID-19. This year’s conference will be held in Los Angeles from October 16-19, 2024.